Medplus Health Services sees 49 lakh shares pledged by Catalyst Trusteeship

Catalyst Trusteeship Limited has disclosed the creation of a pledge over 49,00,000 equity shares of medplus health services , raising its total encumbered holding to 17.27% of the company’s voting capital. The disclosure, filed with the National Stock Exchange of India Limited and BSE Limited on July 28, 2026, reveals that the pledge was created on June 24, 2026, in favor of Catalyst Trusteeship Limited acting as Debenture Trustee for the benefit of debenture holders.

The filing was made pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Deesha Srikanth, Senior Vice President at Catalyst Trusteeship Limited, signed the disclosure from Mumbai. The document confirms that Catalyst Trusteeship Limited does not belong to the promoter or promoter group of Medplus Health Services Limited.

Pledge Details

Prior to this transaction, Catalyst Trusteeship Limited held an encumbrance over 1,58,50,400 shares, which constituted 13.19% of the total share capital and 13.18% of the diluted share capital. The new pledge of 49,00,000 shares adds 4.08% to both the total and diluted voting capital metrics.

Metric	Before Pledge	New Pledge	After Pledge
Encumbered Shares	1,58,50,400	49,00,000	2,07,50,400
% of Total Capital	13.19%	4.08%	17.27%
% of Diluted Capital	13.18%	4.08%	17.26%

Following the transaction, the total number of shares encumbered with the acquirer stands at 2,07,50,400. This represents 17.27% of the total share/voting capital and 17.26% of the total diluted share/voting capital of the target company.

Capital Structure Context

The disclosure notes that the equity share capital of Medplus Health Services Limited remained unchanged at Rs. 24,02,74,122, comprising 12,01,37,061 equity shares with a face value of Rs 2 each. The total diluted share/voting capital is recorded at Rs. 24,04,75,502, corresponding to 12,02,37,751 equity shares assuming full conversion of outstanding convertible securities or warrants.

No shares carrying voting rights were acquired or sold during this period; the change in holding is solely due to the creation of the pledge. The mode of acquisition is specified as "by way of creation of pledge over shares."

What the Numbers Show

The increase in pledged shares indicates a tightening of security for existing debenture holders. With nearly 17.3% of the company's voting power now encumbered in favor of debenture trustees, any default on the underlying debt instruments could lead to significant changes in shareholding structure. The fact that the trustee is not part of the promoter group suggests these pledges are likely related to institutional financing rather than promoter liquidity issues, though the specific debt instrument details are not elaborated in this regulatory filing.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.27%	-12.56%	-12.59%	-9.49%	-22.03%	-37.51%

MedPlus Health Services Limited disclosed on July 26, 2026, that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license in Karnataka. The regulatory action affects a single store located at Busstand Road, Bijapur, and carries a quantifiable financial impact, with the company estimating a potential revenue loss of ₹0.29 lacs. This incident highlights operational compliance risks within the pharmacy chain’s network, although the limited duration and monetary value suggest contained immediate consequences.

The order was issued by the Assistant Director, Drugs Control Administration, Vijayapura Circle, Vijayapura, Karnataka. The authority cited violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. MedPlus received the communication on July 25, 2026, and subsequently filed the disclosure with the stock exchanges to comply with transparency norms.

Regulatory and Financial Details

The disclosure was made pursuant to Regulation 30 read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026. The specific details of the action are outlined below:

Authority	Action Taken	Date of Receipt	Violation Details	Financial Impact
Assistant Director, Drugs Control Administration, Vijayapura Circle, Vijayapura, Karnataka	Suspension of Drug License for two days for store at Busstand Road, Bijapur	July 25, 2026	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Potential Revenue Loss of ₹0.29 lacs

The Company Secretary and Compliance Officer, Shrenik Soni, signed the filing, confirming the information is available on the company’s website as well as those of the BSE and NSE. The brief two-day suspension indicates a procedural or minor compliance lapse rather than a systemic failure, given the low financial exposure.

What the Numbers Show

The estimated revenue loss of ₹0.29 lacs is negligible relative to the overall scale of MedPlus Health Services Limited’s operations, suggesting that this isolated incident will not materially affect the consolidated financial results. However, it underscores the importance of strict adherence to local drug control regulations across all franchise and owned stores. The specificity of the violation—Rule 65 of the Drugs and Cosmetics Act—typically relates to conditions of storage or sale, implying a need for targeted operational review at the affected location rather than a broad strategic overhaul.